Literature DB >> 15645711

Ubiquitin system-dependent regulation of growth hormone receptor signal transduction.

G J Strous1, C Alves dos Santos, J Gent, R Govers, M Sachse, J Schantl, P van Kerkhof.   

Abstract

The growth hormone (GH) receptor is a key regulator of cellular metabolism. Unlike most growth factor receptors, its downregulation is not initiated by its ligand. Like many growth factor receptors, specific molecular mechanisms guarantee that a receptor can signal only once in its lifetime. Three features render the GH receptor unique: (a) an active ubiquitination system is required for both uptake (endocytosis) and degradation in the lysosomes; (b) uptake of the receptor is a continuous process, independent of both GH binding and Jak2 signal transduction; (c) only the cell surface expression of dimerised GH receptors is controlled by the ubiquitin system. This system enables two independent regulatory mechanisms for the endocrinology of the GH/GHR axis: the pulsatile secretion of GH by the pituitary and the GH sensitivity of individual cells of the body by the effects of the ubiquitin system on GH receptor availability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15645711     DOI: 10.1007/978-3-540-69494-6_4

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  4 in total

Review 1.  Ubiquitin-dependent endocytosis, trafficking and turnover of neuronal membrane proteins.

Authors:  Lindsay A Schwarz; Gentry N Patrick
Journal:  Mol Cell Neurosci       Date:  2011-08-22       Impact factor: 4.314

2.  Fos-Zippered GH Receptor Cytosolic Tails Act as Jak2 Substrates and Signal Transducers.

Authors:  Tobias Nespital; Lieke M van der Velden; Anneloes Mensinga; Elisabeth D van der Vaart; Ger J Strous
Journal:  Mol Endocrinol       Date:  2016-02-09

3.  The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels.

Authors:  Mattias Vesterlund; Fahad Zadjali; Torbjörn Persson; Michael Lund Nielsen; Benedikt M Kessler; Gunnar Norstedt; Amilcar Flores-Morales
Journal:  PLoS One       Date:  2011-09-29       Impact factor: 3.240

Review 4.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.